Corestem’s Lou Gehrig disease treatment becomes orphan drug in EU
  • Date 2019-04-08 15:46:10
  • View 1047
Corestem’s Lou Gehrig disease treatment becomes orphan drug in EU

Corestem said Wednesday that NeuroNata-R, its Lou Gehrig's disease therapy, also known as amyotrophic lateral sclerosis (ALS) treatment, has won orphan drug designation (ODD) in the EU.
NeuroNata-R is a stem cell treatment for Lou Gehrig's disease that slows down the speed of body function’s decline by 50 percent after six months of prescription in a clinical trial. The drug received ODD in the U.S. in November last year and won sales approval in Korea in 2015.
For more information, please visit the website
List




Previous ‘Korea’s biopharma sector has sufficient potential’
Next Korean companies excel multinational pharma’s R&D in investment-sales ratio

�붠겉�克戟筠�� 劇逵均逵鈞龜戟 Blacksprut Free ebooks Library zlib project z-library Z-Library project Immediate Affinity

Discover the real world of gambling for Korean players at bons casino, a licensed online casino! Hundreds of exciting games for every taste are waiting for you. From classic slots with reels to games with live dealers. BONS Casino offers registration bonuses, free spins, deposit extra funds for games with live dealers, and other promotions! Play and score at BONS CASINO now!

Bitcore Momentum

Casino news

Turkey Slots News Turkey Aviator News Turkey Slots News Turkey Casino News